Drug Profile


Latest Information Update: 02 Jul 2001

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Developer Nonindustrial source; Ono Pharmaceutical
  • Class Anticoagulants; Guanidines; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Spinal cord injuries

Most Recent Events

  • 02 Jul 2001 No-Development-Reported for Spinal cord injuries in Japan (Unknown route)
  • 29 Jul 1997 New profile
  • 29 Jul 1997 Preclinical development for Spinal cord injuries in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top